What is the standard dosage of ketoanalogue (ketogenic amino acid analog) formulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Standard Ketoanalogue Dosage

The standard dosage of ketoanalogue formulation is 1 tablet per 5 kg body weight per day, typically administered in conjunction with a low-protein diet (0.3-0.6 g/kg/day). 1

Dosing Specifications

Standard Formulation (Ketosteril)

  • Dosage: 1 tablet per 5 kg body weight per day 2
  • This translates to approximately 0.2 tablets/kg/day for practical calculation
  • Administered as part of a comprehensive dietary protein restriction strategy 1

Protein Restriction Context

The ketoanalogue dosing must be paired with appropriate protein restriction based on CKD stage 1:

  • Very Low-Protein Diet (sVLPD): 0.3-0.4 g/kg/day (vegetarian) with ketoanalogue supplementation at 1 tablet/5 kg/day 3
  • Low-Protein Diet (sLPD): 0.6 g/kg/day with the same ketoanalogue dosing 4

Evidence-Based Dosing Thresholds

Higher dosages show superior clinical outcomes 5:

  • Dosages >5.5 tablets per day demonstrate significantly reduced risk of dialysis initiation and mortality 5
  • This corresponds to patients weighing >27.5 kg requiring this minimum threshold for optimal benefit 5

Practical Calculation Example

For a 70 kg patient:

  • Standard dose: 70 kg ÷ 5 = 14 tablets per day 2
  • This exceeds the therapeutic threshold of 5.5 tablets, providing optimal benefit 5

Clinical Application by CKD Stage

CKD Stage 4-5 (Pre-dialysis) 1:

  • Initiate at 1 tablet/5 kg/day with protein restriction
  • Essential amino acids and ketoanalogues are specifically proposed to preserve renal function in conservatively treated CKD patients 1

Duration Considerations 1:

  • For enteral nutrition <5 days: standard formulae acceptable
  • For enteral nutrition ≥5 days: disease-specific formulae with ketoanalogues recommended 1

Important Clinical Caveats

Continuation is critical 4:

  • Patients must continue ketoanalogue supplementation for >3 months to achieve significant reduction in dialysis risk 4
  • Discontinuation before 3 months negates the protective benefits 4

Monitoring requirements 1:

  • Strict monitoring of energy intake and nutritional status essential to prevent undernutrition 1
  • Low-protein diets with ketoanalogues require careful oversight to avoid protein-energy wasting 1

Age-specific benefits 6:

  • Mortality risk reduction appears more prominent in patients ≥70 years old (adjusted HR: 0.65) compared to younger patients (adjusted HR: 0.82) 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.